Source: British Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Subjects: NEFROPATIAS, FARMACOCINÉTICA, FENÓTIPOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NEVES, Daniel V. et al. Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers. British Journal of Clinical Pharmacology, v. 82, n. 1, p. 83-91, 2016Tradução . . Disponível em: https://doi.org/10.1111/bcp.12917. Acesso em: 10 jun. 2024.APA
Neves, D. V., Lanchote, V. L., Moysés Neto, M., Costa, J. A. C. da, Vieira, C. P., & Coelho, E. B. (2016). Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers. British Journal of Clinical Pharmacology, 82( 1), 83-91. doi:10.1111/bcp.12917NLM
Neves DV, Lanchote VL, Moysés Neto M, Costa JAC da, Vieira CP, Coelho EB. Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers [Internet]. British Journal of Clinical Pharmacology. 2016 ; 82( 1): 83-91.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1111/bcp.12917Vancouver
Neves DV, Lanchote VL, Moysés Neto M, Costa JAC da, Vieira CP, Coelho EB. Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers [Internet]. British Journal of Clinical Pharmacology. 2016 ; 82( 1): 83-91.[citado 2024 jun. 10 ] Available from: https://doi.org/10.1111/bcp.12917
